Joshi SK, Huang A, Pittsenbarger J, Shinde U, Posso C, Piehowski PD, Gosline SJ, Press RD, Gritsenko MA, Hutchinson C, Weitz KK, Watanabe-Smith K, Long N, Rodland KD, Tyner JW, Druker BJ, Tognon CE. Oncogenic NTRK3 mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia. Haematologica 2025;110(7):1616-1622; https://doi.org/10.3324/haematol.2024.285572.